Yartemlea (narsoplimab-wuug) (New)

By May 15, 2026: Billing team and clinical staff must implement prior authorization procedures for Yartemlea (narsoplimab-wuug) claims submitted to Humana Indiana Medicaid. Update billing system to flag all Yartemlea requests as requiring prior authorization before claim submission. Ensure that prescribing providers document patient diagnosis of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in clinical notes and include it on prior authorization requests. Providers must submit prior auth requests through Humana's PAL system (www.humana.com/PAL) before dispensing the medication. Train front desk and billing staff on the new requirement. Note that approval duration is plan year or as determined through clinical review, with renewals also requiring authorization. Claims submitted without prior authorization will be denied by Humana Indiana Medicaid.